首页 | 本学科首页   官方微博 | 高级检索  
     

赛利司他(ATL-962)、利莫那班和赛尼可的研发与市场趋势
引用本文:阎家麒,高荣,谢建平,Jianping. 赛利司他(ATL-962)、利莫那班和赛尼可的研发与市场趋势[J]. 化工时刊, 2008, 22(2): 72-73
作者姓名:阎家麒  高荣  谢建平  Jianping
作者单位:泰州市今朝伟业精细化工有限公司,江苏,泰州,225327;泰州市今朝伟业精细化工有限公司,江苏,泰州,225327;泰州市今朝伟业精细化工有限公司,江苏,泰州,225327;泰州市今朝伟业精细化工有限公司,江苏,泰州,225327
摘    要:本文阐述了赛利司他、利莫那班和赛尼可3种新减肥药物的研发和市场趋势,同时对这3种减肥药物作了疗效比较,并对各种药物的优缺点进行了分析。赛利司他和利莫那班蕴藏着巨大商机,尤其是脂肪酶抑制剂赛利司他。

关 键 词:赛利司他  利莫那班  赛尼可  减肥药物
收稿时间:2007-08-27
修稿时间:2007-08-27

Research and Development and Market Trends of Anti-obesity Drugs such as Cetilistat(ATL-962),Rimonabant and Xenical
Yan Jiaqi,Gao Rong,Xie,Jianping. Research and Development and Market Trends of Anti-obesity Drugs such as Cetilistat(ATL-962),Rimonabant and Xenical[J]. Chemical Industry Times, 2008, 22(2): 72-73
Authors:Yan Jiaqi  Gao Rong  Xie  Jianping
Affiliation:Yan Jiaqi Gao Rong Xie Jianping (Taizhou Jinzhaoweiye Fine Chernieals Co., Ltd., Jiangsu Taizhou 225327)
Abstract:The research and development of three new anti-obesity drugs such as Cetilitat(ATL-962), Rimonabant and Xenical and their current market trends were presented. Meanwhile, the three drugs effects in administration and the advantages and disadvantages of each were analyzed. Cetilitat (ATL-962), Rimonabant had the potential to greatly enhance the market opportunity for lipase inhibitors and thus the potential for Cetilistat.
Keywords:Cetilitat(ATL-962) Rimonabant Xenical anti-obesity drugs
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号